Skip to main
MIRM
MIRM logo

MIRM Stock Forecast & Price Target

MIRM Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 38%
Buy 63%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Mirum Pharmaceuticals Inc. reported net sales revenue of $64.1 million for LIVMARLI in the fourth quarter of 2024, reflecting an 8.4% growth from the previous quarter and a substantial 54.5% increase from the fourth quarter of 2023. The company anticipates continued growth in LIVMARLI's net sales, particularly from the progressive familial intrahepatic cholestasis (PFIC) indication, which is expected to contribute an estimated $15 million in revenue for the full year of 2025. Additionally, the promising interim results from the VANTAGE study for volixibat highlight the potential for further market expansion and positive cash flow, bolstering confidence in Mirum’s financial outlook and growth prospects.

Bears say

Mirum Pharmaceuticals faces significant financial risks that contribute to a negative outlook on its stock, including the potential for sales growth of its primary products, Livmarli and volixibat, to fall well below expectations. The company reported a FY2024 net loss of $87.9 million, driven by substantial operating expenses totaling $140.6 million in research and development and $202.2 million in selling, general, and administrative costs, which may necessitate additional capital raising and lead to share dilution. Moreover, challenges related to regulatory approvals, trial results, and the competitive landscape for its pipeline candidates could hinder commercial uptake, delaying any path to profitability and exacerbating financial instability.

MIRM has been analyzed by 16 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 63% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Mirum Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Mirum Pharmaceuticals Inc (MIRM) Forecast

Analysts have given MIRM a Buy based on their latest research and market trends.

According to 16 analysts, MIRM has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $59.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $59.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Mirum Pharmaceuticals Inc (MIRM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.